FROM GUIDELINES TO BREAKTHROUGHS – OPTIMIZING TREATMENT OPTIONS FOR PATIENTS WITH HCM (AS-102)

Saturday, October 28, 2023

12:30 – 13:30 EST

Location: Palais, 517A

Target Audience: Community cardiologists, cardiologists and other HCPs who would like to further their knowledge in HCM

Co-Chair : AS(s)

MC

Michael Chetrit

Cardiologist
MUHC
McGill University
Anil Gupta

Cardiologist
Trillum Health Partners
Trillum Health Partners
Gillian Nesbitt, MD, FRCPC, FASE, FACC

Associate Professor
CSE
University of Toronto

Presenter : AS(s)

Kim Anderson, MD (she/her/hers)

Assistant Professor
CHFS, CCTN
Dalhousie University
PG

Patrick Garceau
MW

Michael R. Ward, MD, PhD

Clinical Fellow, Interventional Cardiology
University Of Toronto

Disclosure(s):

Michael Chetrit: Abbott: Speaker/Honoraria (Ongoing); Alnylam: Consultant/Advisory Board (Ongoing); BMS: Consultant/Advisory Board (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)

Gillian Nesbitt, MD, FRCPC, FASE, FACC: Bristol Myers Sqibb: Speaker/Honoraria (Ongoing)

Kim Anderson, MD: Alnylam: Consultant/Advisory Board (Terminated, October 31, 2022), Speaker/Honoraria (Terminated, October 31, 2022); Amgen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Astra-Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boehringer-Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Bristol-Myers Squibb: Consultant/Advisory Board (Ongoing); Luitpold: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Merck: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Takeda: Speaker/Honoraria (Terminated, October 31, 2022)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

discuss the clinical management of HCM;
summarize the evidence on current and new medical therapies and discuss how to integrate them into clinical practice; and
examine alternative therapeutic strategies for patients who are refractory to medical therapies.

Session Description: This symposium is intended for cardiologists, endocrinologists, diabetologists, internists, family physicians, residents, and allied health professionals and will focus on current and emerging treatment options for hypertrophic cardiomyopathy (HCM). Through discussion of didactic content, clinical data, and case scenarios, this symposium will shed light on current and emerging pharmacotherapies and invasive treatment options for HCM, as well as provide guidance on how to integrate new therapies into clinical practice to optimize treatment outcomes in patients with HCM.